Slow tamoxifen uptake for prevention

Oncologist Professor Ian Olver, CEO of Cancer Council Australia, said he understood the reasons for slow uptake of SERMs.

“Prevention messages have mostly been about lifestyle changes,” he said.

“Not terribly many have been about taking medicines.”

A large meta-analysis has found tamoxifen, raloxifene, arzoxifene and lasofoxifene significantly reduced the risk of developing invasive oestrogen (ER)-positive breast cancer among